Key Highlights

  • The Celularity license and asset purchase closed April 17, 2026 for $13.3 million upfront, with up to $17.5 million of further milestones outstanding.
  • Sequence LifeScience's $5.5 million anchored a private placement of 10% convertible notes; total note principal reached $15.085 million.
  • NEXGEL held $208 thousand of unrestricted cash at March 31, 2026, carries going-concern doubt, and faces a Nasdaq bid-price deadline of October 19, 2026.
  • NEXGEL postponed its annual meeting to July 31, 2026 to gather proxies.

Why NEXGEL, Inc. Is Drawing Investor Attention

NEXGEL, Inc. has long been a specialist manufacturer with a narrow story: it makes electron-beam, cross-linked hydrogels in Langhorne, Pennsylvania, sells them to other companies, and layers a few consumer brands on top. Full-year 2025 revenue was $11.4 million. In April 2026 it licensed and acquired a portfolio of commercial-stage regenerative biomaterials from Celularity Inc., telling shareholders the deal should roughly triple its revenue base to about $35 million on a pro-forma basis.

What makes this interesting rather than promotional is the gap between the ambition and the balance sheet carrying it. The company entered the transaction with $208 thousand of unrestricted cash, an accumulated deficit of $21.9 million, going-concern language in its filings, and a share price below Nasdaq's $1.00 threshold.

Inside the Business: What NEXGEL Actually Does

NEXGEL describes four lines of business. Contract manufacturing sells rolls of hydrogel to third parties who convert them into finished goods, while custom and white label work delivers a finished unit a customer brands. Consumer branded products sell online under the Medagel family, plus Kenkoderm, a psoriasis skincare line acquired in December 2023, and Silly George, an eye-beauty brand acquired in May 2024. The fourth line, medical devices, is largely pre-commercial.

In the March 2026 quarter that mix was consumer branded products $1.62 million, contract manufacturing $916 thousand and medical devices and other $113 thousand. The Langhorne plant occupies 13,500 square feet and the 10-K states it runs at roughly 15 to 20 percent of capacity, which management frames as headroom rather than idle cost.

The 10-K is explicit on concentration: in each of 2025 and 2024, no single customer reached 10 percent of revenue. The most substantive named partner is STADA Arzneimittel AG, which agreed in July 2025 to advance $1 million of non-dilutive capital.

The $5.5 Million Sequence LifeScience Investment and the Celularity Biomaterials Deal

The sequence of events matters. On February 10, 2026 NEXGEL announced a $1.797 million financing tied to an unnamed acquisition, with funds returnable if no transaction closed. On March 6 it signed an Asset Purchase and Exclusive License Agreement with Celularity Inc. for up to $35.0 million, a $15.0 million upfront payment plus $20.0 million of net-sales milestones, conditioned on raising enough to fund the upfront.

It could not raise $15.0 million. On April 17, 2026 the parties signed Amendment No. 1, cutting the upfront to $13.3 million: $8.3 million in cash plus a $5.0 million convertible promissory note issued to Celularity. Up to $17.5 million of milestones remain. The transaction closed the same day and was reported under Item 2.01 in a Form 8-K filed April 21.

How the $5.5 million fits

The headline figure is real but narrower than it sounds. Sequence LifeScience, a Texas human-tissue manufacturer, made a $5.5 million strategic investment that led, and did not constitute, the financing. The April 17 private placement was sold under Rule 506(b) and comprised unsecured convertible notes of $7.375 million including subsequent closings, with a further $1.21 million issued on May 11. Including the seller note, aggregate principal reached $15.085 million. Neither net proceeds nor fees were quantified.

The terms are the story. The notes pay 10 percent, mature 18 months from issuance, and convert at $0.60, resetting at twelve months and again at maturity to the lower of the then-current price or a five-day volume-weighted average, with no floor and full-ratchet anti-dilution protection. Warrants covering half the underlying shares carry an $0.80 strike. Insiders participated, including $1.0 million taken by Sequence's principal, who joined the board on May 6.

Two things remain unproven. Sequence will also act as contract manufacturer to BioNX Surgical, aligning interests but concentrating them. And as of July 26, 2026 the audited financials required by Item 9.01 had not been filed, so the $35 million figure rests on forward-looking statements.

Latest Financial and Operational Performance

The most recent reported period is the quarter ended March 31, 2026, disclosed in the Form 10-Q filed May 14, 2026 rather than through an earnings release. Revenue was $2.65 million, down from $2.81 million a year earlier, with the decline in consumer branded products. Gross profit was $1.06 million, a margin near 40 percent against 42 percent. The loss from operations widened to $958 thousand from $777 thousand, and the loss attributable to stockholders was $927 thousand, or $0.11 per share.

Because the quarter ended before the closing, none of the acquired portfolio appears in those figures; the first combined period is the quarter ending June 30, 2026.

For 2025, revenue rose 31.5 percent to $11.42 million, driven mainly by a full year of Silly George, and gross margin improved to 39.5 percent from 31.6 percent. Selling, general and administrative expense climbed 26.3 percent to $7.86 million, however, producing a $3.35 million operating loss.

Balance Sheet, Cash Position and Funding

At March 31, 2026 NEXGEL held $208 thousand of unrestricted cash, down from $317 thousand at the end of 2025, alongside $1.91 million of restricted cash largely representing escrowed financing proceeds. Total liabilities were $7.12 million and the accumulated deficit stood at $21.92 million.

The Form 10-Q states plainly that these conditions raise substantial doubt about the company's ability to continue as a going concern, while noting the April raise and management's expectation of positive operating cash flow from the acquired business. No post-closing pro-forma cash figure has been published, and $8.3 million went straight out to Celularity, so the raise is not a cash cushion.

Historical dilution has been contained: rights offerings brought in $3.77 million in 2024 and $963 thousand in 2025, and shares outstanding moved from 8,143,133 at December 31, 2025 to 9,225,242 by June 3, 2026. The forward risk sits in the convertible stack, not the history.

Growth Opportunities and Upcoming Milestones

The acquired portfolio comprises six commercial-stage regenerative biomaterial products addressing tendon repair, soft tissue reconstruction and bone regeneration, which the company says carry more than a decade of clinical use and existing reimbursement. Three further 510(k) submissions are planned for 2026, 2027 and 2028. That shifts NEXGEL's regulatory posture: its 10-K notes hydrogels are generally Class I exempt devices sold as components, whereas cleared devices and human tissue products carry a heavier quality-system burden.

The nearer-term calendar is corporate. NEXGEL postponed its annual meeting to July 31, 2026 to gather proxies. Shareholders are asked to approve issuance above the 19.99 percent Nasdaq cap, reincorporation from Delaware to Nevada, and, as fallbacks, raising authorized shares to 100 million and a discretionary reverse split of between 1-for-2 and 1-for-10.

Material Risks Specific to NEXGEL

A Balanced Outlook: Upside, Base Case and Downside

Upside

Shareholders approve the Nasdaq and charter proposals, the coming filings show the acquired portfolio delivering revenue and margin in line with management's commentary, and reimbursed biomaterials volume funds operations. The notes then convert rather than come due.

Base case

Integration proves messier than the press releases imply. The combined run rate lands below the $35 million reference, legacy consumer brands keep drifting, and management relies on a reverse split to restore compliance while conversions expand the share count.

Downside

Approval slips or the share price falls far enough that the twelve-month reset multiplies the conversion shares. Milestone obligations and interest compete with working capital, the acquired sales organization does not retain, and a delisting determination arrives alongside a financing on worse terms.

Conclusion

NEXGEL, Inc. (NASDAQ:NXGL) has done the hard part of any small-cap transformation: the Celularity purchase actually closed. What it has not done is demonstrate the economics. The $5.5 million Sequence LifeScience investment anchored a financing that loaded $15.085 million of resetting convertible debt onto a company with $208 thousand of unrestricted cash and a bid-price clock running to October 19, 2026. The June-quarter results will settle whether the hydrogel platform has changed leagues.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.